

0980371 0940802
09/890371

1/24

Intranasal application of Transfersulin
IDDM test person, ~0.8 IU/kg




Fig. 1

2/24

Intranasal application of Transfersulin
on a normoglycaemic test person, ~ 0.15 IU/kg (2x)




Fig. 2

3/24




Fig. 3a

4/24

Intranasal application of Transfersulin
in IDDM test person, ~0.4 IU/kg




Fig. 3b

5/24

Effects of nasally administered
cytokines on specific immune response,
1st boost + 7 d




Fig. 4

6/24




Fig. 5

7/24




Fig. 6

8/24

Intranasal administration: Tetanus toxoid (TT, impure)





Fig. 7a

9/24

Intranasal immunisation: Tetanus toxoid (TT *impure*)

Antigen dose in all the groups : 40 µg per mouse

Fig. 7b

10/24

Intranasal immunisation: *Tetanus toxoid (TT, impure)*
Effect of carrier size and deformability




Fig. 7c

11/24

Intranasal Immunization: Tetanus toxoid, (TT, purified)
dose effect




Fig. 8a

Intranasal immunisation: *Tetanus toxoid (TT, purified)*, Effect of antigen dose




Fig. 8b

Intranasal Immunization: *Tetanus toxoid (TT, purified)*, dose effect

13/24




Fig. 8c




Fig. 9a

15/24

Noninvasive immunisation: Tetanus toxoid (TT, purified)

route of application effect




Fig. 9b

Antigen-specific Isotyping: Intranasal / Subcutaneous

40 μ g Tetanus Toxoid (TT), ultrafiltered




Fig. 9c
Antiserum dilution

17/24

Intranasal immunisation: Tetanus toxoid (TT)
dose and route of administration effect




Fig. 10a

18/24

Intranasal immunisation: Tetanus toxoid (TT, purified) dose effect




Fig. 10b

Intranasal immunisation: Tetanus toxoid (TT, impure)
effect of immunomodulators





Fig. 11a

Intranasal immunisation: *Tetanus toxoid (TT, impure, 40 µg)*, effect of immunomodulators,

— ◊ — i.n. TT in TfS
 — ● — i.n. TT in TfS + IFN- γ
 — ▲ — i.n. TT in TfS + GM-CSF + IL-4
 — ▽ — i.n. TT in TfS + IL-4
 — △ — i.n. TT in TfS + IL-12
 — ■ — s.c. TT in TfS

Fig. 11b

SPC:Tw-80 3.5:1

Intranasal immunisation: Tetanus toxoid (TT, purified)
effect of immunopotentiators




Fig. 12

22/24
Potentiation of nasal immune response to tetanus
toxoid (TT) by bacterial adjuvant, cholera toxin (CT)





Fig. 13

Adjuvant effect: of Heat Labile Toxin (LT) from E.coli

23/24




Fig. 14

**Bi-Valent Vaccines: Anti-Tetanus and -Cholera response
to the antigens administration in Transfersomes in the nose**




Fig. 15